ArticleNature2015
Whole-genome characterization of chemoresistant ovarian cancer.
Erratum issuedAbstract read
In one paragraph
Article in Nature, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 937 papers.
0numbers the graph read from it
0cells of the map it votes in
937citing papers in PubMed
54.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
937 citing papers in PubMed, 1,618 citations in OpenAlex.
- Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.British journal of cancer · 2026Trial
- Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian Cancer.Cancer science · 2026Trial
- Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response-Deficient Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- A photothermal ablation strategy for orthotopic ovarian cancerInternational journal of pharmaceutics: X · 2026Article
- Endogenous replication stress creates a unique therapeutic window for ALC1 targeting.EMBO reports · 2026Article
- CCNE1 overexpression drives a cGAS-STING-dependent interferon response and sensitizes HRD-positive ovarian cancer to immune checkpoint blockade.Journal for immunotherapy of cancer · 2026Article
- The dual immune landscape of homologous recombination-deficient tumors: mechanisms and therapeutic implications.Cancer metastasis reviews · 2026Review
- Mechanisms and disease relevance of DNA break repair pathway choice.Nature reviews. Molecular cell biology · 2026Review
- Review
- PARP16 is a druggable regulator of ribosome MARylation and protein homeostasis in ovarian cancer cells.The Journal of biological chemistry · 2026Article
- Spatiotemporal immune heterogeneity and precision immunotherapy for ovarian cancer.Clinical and translational medicine · 2026Review
- HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- The DNA damage response and cancer immunotherapy.Nature reviews. Cancer · 2026Review
- Single-Cell Transcriptomic Analysis Reveals Ferroptosis-Related Signatures and Tumor Microenvironment Heterogeneity in Epithelial Ovarian Cancer.Cancer medicine · 2026Article
- Podoplanin-positive extracellular vesicles in ovarian cancer: linking thrombosis, platelet crosstalk, and cancer stemness - a narrative review.Annals of medicine and surgery (2012) · 2026Article
- Generation of modified cows and sheep from spermatid-like haploid embryonic stem cells.Nature biotechnology · 2026Article
- From cytoreduction to precision oncology: evolution of ovarian cancer therapy.Journal of ovarian research · 2026Review
- Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Transcriptomic analysis of tissue-resident memory T cells of the fallopian tube reveals a precursor immune surveillance network for ovarian cancer prevention.Nature communications · 2026Article
- PAK1 inhibition synergistically enhances the anti-tumor efficacy of PARP inhibitors in ovarian cancers.Genes & diseases · 2026Article
877 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
83 authors at 13 institutions in 4 countries.
Ann-Marie Patch1] Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia [2] QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia.
Elizabeth L ChristiePeter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Dariush Etemadmoghadam1] Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia [2] Department of Pathology, University of Melbourne, Parkville, Victoria 3052, Australia [3] Sir Peter MacCallum Cancer Centre Department of Oncology, University of Melbourne, Parkville, Victoria 3052, Australia.
Dale W GarsedPeter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Joshy GeorgeThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut 06030, USA.
Sian FeredayPeter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Katia Nones1] Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia [2] QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia.
Prue CowinPeter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Kathryn AlsopPeter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Peter J Bailey1] Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia [2] WolfsonWohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK.
Karin S Kassahn1] Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia [2] Technology Advancement Unit, Genetics and Molecular Pathology, SA Pathology, Adelaide, South Australia 5000, Australia.
Felicity NewellQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia.
Michael C J Quinn1] Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia [2] QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia.
Stephen Kazakoff1] Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia [2] QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia.
Kelly QuekQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia.
Charlotte Wilhelm-BenartziOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London W12 0HS, UK.
Ed CurryOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London W12 0HS, UK.
Huei San LeongPeter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Australian Ovarian Cancer Study Group
Anne Hamilton1] Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia [2] Department of Medicine, University of Melbourne, Parkville, Victoria 3052, Australia [3] The Royal Women's Hospital, Parkville, Victoria 3052, Australia.
Linda Mileshkin1] Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia [2] Sir Peter MacCallum Cancer Centre Department of Oncology, University of Melbourne, Parkville, Victoria 3052, Australia.
George Au-YeungPeter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Catherine KennedyCentre for Cancer Research, University of Sydney at Westmead Millennium Institute, and Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales 2145, Australia.
Jillian HungCentre for Cancer Research, University of Sydney at Westmead Millennium Institute, and Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales 2145, Australia.
Yoke-Eng ChiewCentre for Cancer Research, University of Sydney at Westmead Millennium Institute, and Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales 2145, Australia.
Paul HarnettCrown Princess Mary Cancer Centre and University of Sydney at Westmead Hospital, Westmead, Sydney, New South Wales 2145, Australia.
Michael FriedlanderPrince of Wales Clinical School, University of New South Wales, Sydney, New South Wales 2031, Australia.
Michael QuinnThe Royal Women's Hospital, Parkville, Victoria 3052, Australia.
Jan PymanThe Royal Women's Hospital, Parkville, Victoria 3052, Australia.
Stephen CordnerVictorian Institute of Forensic Medicine, Southbank, Victoria 3006, Australia.
Patricia O'BrienVictorian Institute of Forensic Medicine, Southbank, Victoria 3006, Australia.
Jodie LeditschkeVictorian Institute of Forensic Medicine, Southbank, Victoria 3006, Australia.
Greg YoungVictorian Institute of Forensic Medicine, Southbank, Victoria 3006, Australia.
Kate StrachanVictorian Institute of Forensic Medicine, Southbank, Victoria 3006, Australia.
Paul WaringDepartment of Pathology, University of Melbourne, Parkville, Victoria 3052, Australia.
Walid AzarPeter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Chris MitchellPeter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Nadia TraficantePeter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Joy HendleyPeter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Heather ThornePeter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Mark Shackleton1] Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia [2] Sir Peter MacCallum Cancer Centre Department of Oncology, University of Melbourne, Parkville, Victoria 3052, Australia.
David K MillerQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia.
Gisela Mir ArnauPeter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Richard W Tothill1] Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia [2] Sir Peter MacCallum Cancer Centre Department of Oncology, University of Melbourne, Parkville, Victoria 3052, Australia.
Timothy P HollowayPeter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Timothy SemplePeter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Ivon HarliwongQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia.
Craig NourseQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia.
Ehsan NourbakhshQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia.
Suzanne ManningQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia.
Senel IdrisogluQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia.
Timothy J C BruxnerQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia.
Angelika N ChristQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia.
Barsha PoudelQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia.
Oliver Holmes1] Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia [2] QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia.
Matthew AndersonQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia.
Conrad Leonard1] Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia [2] QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia.
Andrew LonieVictorian Life Sciences Computation Initiative, Carlton, Victoria 3053, Australia.
Nathan HallLa Trobe Institute for Molecular Science, Bundoora, Victoria 3083, Australia.
Scott Wood1] Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia [2] QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia.
Darrin F TaylorQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia.
Qinying Xu1] Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia [2] QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia.
J Lynn FinkQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia.
Nick WaddellQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia.
Ronny DrapkinDana-Farber Cancer Institute, Boston, Massachusetts 02115-5450, USA.
Euan StronachOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London W12 0HS, UK.
Hani GabraOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London W12 0HS, UK.
Robert BrownOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London W12 0HS, UK.
Andrea JewellUniversity of Chicago, Chicago, Illinois 60637, USA.
Shivashankar H NagarajQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia.
Emma MarkhamQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia.
Peter J WilsonQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia.
Jason EllulPeter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Orla McNallyCentre for Cancer Research, University of Sydney at Westmead Millennium Institute, and Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales 2145, Australia.
Maria A DoylePeter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Ravikiran VedururuPeter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Collin StewartThe University of Western Australia, Crawley, Western Australia 6009, Australia.
Ernst LengyelUniversity of Chicago, Chicago, Illinois 60637, USA.
John V Pearson1] Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia [2] QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia.
Nicola Waddell1] Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia [2] QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia.
Anna deFazioCentre for Cancer Research, University of Sydney at Westmead Millennium Institute, and Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales 2145, Australia.
Sean M Grimmond1] Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4067, Australia [2] WolfsonWohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK.
David D L Bowtell1] Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia [2] Department of Pathology, University of Melbourne, Parkville, Victoria 3052, Australia [3] Sir Peter MacCallum Cancer Centre Department of Oncology, University of Melbourne, Parkville, Victoria 3052, Australia [4] Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London W12 0HS, UK [5] Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria 3052, Australia.
The University of Queensland · AUPeter MacCallum Cancer Centre · AUMillennium Institute · BRQIMR Berghofer Medical Research Institute · AURoyal Women's Hospital · AUOvarian Cancer Action · GBVictorian Institute of Forensic Medicine · AULa Trobe University · AUThe University of Melbourne · AUThe University of Western Australia · AUJackson Laboratory · USUniversity of Chicago · USWestmead Hospital · AU
Funding
Cancer Research UK 13086Cancer Research UK 15954Worldwide Cancer Research 11-0748
Abstract
Patients with high-grade serous ovarian cancer (HGSC) have experienced little improvement in overall survival, and standard treatment has not advanced beyond platinum-based combination chemotherapy, during the past 30 years. To understand the drivers of clinical phenotypes better, here we use whole-genome sequencing of tumour and germline DNA samples from 92 patients with primary refractory, resistant, sensitive and matched acquired resistant disease. We show that gene breakage commonly inactivates the tumour suppressors RB1, NF1, RAD51B and PTEN in HGSC, and contributes to acquired chemotherapy resistance. CCNE1 amplification was common in primary resistant and refractory disease. We observed several molecular events associated with acquired resistance, including multiple independent reversions of germline BRCA1 or BRCA2 mutations in individual patients, loss of BRCA1 promoter methylation, an alteration in molecular subtype, and recurrent promoter fusion associated with overexpression of the drug efflux pump MDR1.
Indexed as
ATP Binding Cassette Transporter, Subfamily B, Member 1Cohort StudiesCyclin ECystadenocarcinoma, SerousDNA-Binding ProteinsDNA MethylationDNA Mutational AnalysisDrug Resistance, NeoplasmFemaleGenes, BRCA1Genes, BRCA2Genes, Neurofibromatosis 1Genome, HumanGerm-Line MutationHumansMutagenesisATP Binding Cassette Transporter, Subfamily B, Member 1CCNE1 protein, humanCyclin EDNA-Binding ProteinsOncogene ProteinsPTEN PhosphohydrolasePTEN protein, humanRAD51B protein, humanRetinoblastoma Protein
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.